Every medicine authorised for the Irish market — 10,165 products with active substances, licence holders, dosage forms and prescription status.
| Medicine | Active substance | Licence holder | Status |
|---|---|---|---|
| LIBTAYO 350 mg Concentrate for solution for infusion EU/1/19/1376/001 |
CEMIPLIMAB | Regeneron Ireland U.C. | — |
| LYNOZYFIC 200 mg concentrate for solution for infusion EU/1/25/1917/002 |
Linvoseltamab | Regeneron Ireland Designated Activity Company | — |
| LYNOZYFIC 5 mg concentrate for solution for infusion EU/1/25/1917/001 |
Linvoseltamab | Regeneron Ireland Designated Activity Company | — |
| Ordspono 2 mg Concentrate for solution for infusion EU/1/24/1843/001 |
Odronextamab | Regeneron Ireland Designated Activity Company | — |
| Ordspono 320 mg Concentrate for solution for infusion EU/1/24/1843/003 |
Odronextamab | Regeneron Ireland Designated Activity Company | — |
| Ordspono 80 mg Concentrate for solution for infusion EU/1/24/1843/002 |
Odronextamab | Regeneron Ireland Designated Activity Company | — |
Priya Life Science (2026). Irish Medicines Database. Available at: https://priyalifescience.com/medicines (Accessed: 13 August 2026).
Data: Health Products Regulatory Authority (HPRA) open dataset (“Authorised or Transfer Pending Products”), licensed CC BY 4.0, refreshed daily. Regulatory information only — not medical advice.